Document Detail


Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.
MedLine Citation:
PMID:  10632308     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Women with new vertebral fractures have an increased risk of back pain and functional limitation because of back pain. Alendronate sodium treatment reduces the risk of new vertebral fracture by 50% in postmenopausal women with osteoporosis. OBJECTIVE: To determine the effect of alendronate therapy on days affected by back pain in postmenopausal women with existing vertebral fractures. DESIGN: Three-year, placebo-controlled, randomized, double-blind study. SETTING: Fifteen university-based research clinics in the United States. PARTICIPANTS: A total of 2027 postmenopausal women aged 55 to 81 years with low femoral neck bone density and a preexisting vertebral fracture. INTERVENTION: Alendronate sodium (5 mg/d for 2 years and 10 mg/d for the third year) or placebo. MAIN OUTCOME MEASURES: Occurrence and severity of back pain, number of days with back pain, and number of days of bed rest or limited activity because of back pain during 3 years of follow-up. RESULTS: Irrespective of treatment assignment, women with new, clinically recognized vertebral fractures during follow-up had an increased risk of days of bed disability and days of limited activity because of back pain after the fracture. Women receiving alendronate reported an average of 3.2 fewer days of bed rest (P = .001) and 11.4 fewer days of limited activity (not including days of bed rest) because of back pain (P = .04) during follow-up than those receiving placebo. In the alendronate group, relative to the placebo group, there was a reduced risk of 1 or more bed-rest days (relative risk, 0.68; 95% confidence interval, 0.53-0.87), of 7 or more bed-rest days (0.44; 0.30-0.64), and of 7 or more limited-activity days (0.87; 0.76-0.99). There were no statistically significant differences between treatment groups in the frequency of days of back pain or increases in back-related disability between baseline and study end. CONCLUSION: In postmenopausal women with preexisting vertebral fracture, alendronate therapy for 3 years reduced the number of days of bed disability and days of limited activity caused by back pain.
Authors:
M C Nevitt; D E Thompson; D M Black; S R Rubin; K Ensrud; A J Yates; S R Cummings
Related Documents :
17229348 - Vertebral plate regeneration induced by radiation-sterilized allogeneic bone sheets in ...
20221618 - Indications and contraindications for vertebroplasty and kyphoplasty.
21655758 - Earthquake-related pelvic crush fracture vs. non-earthquake fracture on digital radiogr...
19082528 - Randomized controlled study on the prevention of osteoporotic fractures (of study): a p...
12661898 - Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast can...
12058578 - Pneumatized spaces, sinuses and spongy bones in the skulls of primates.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of internal medicine     Volume:  160     ISSN:  0003-9926     ISO Abbreviation:  Arch. Intern. Med.     Publication Date:  2000 Jan 
Date Detail:
Created Date:  2000-01-28     Completed Date:  2000-01-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372440     Medline TA:  Arch Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  77-85     Citation Subset:  AIM; IM; S    
Affiliation:
Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA. mnevitt@psg.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activities of Daily Living
Aged
Alendronate / therapeutic use*
Back Pain / drug therapy*,  etiology
Bed Rest*
Bone Density / drug effects
Double-Blind Method
Female
Humans
Incidence
Middle Aged
Osteoporosis, Postmenopausal / complications*
Risk
Severity of Illness Index
Spinal Fractures / complications*,  etiology*
Treatment Outcome
Chemical
Reg. No./Substance:
66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Organizational and financial characteristics of health plans: are they related to primary care perfo...
Next Document:  Invasive pneumococcal infection in Baltimore, Md: implications for immunization policy.